Investor Alert

Market Pulse Archives

July 29, 2021, 6:49 a.m. EDT

Merck stock slips after adjusted profit matches expectations, while revenue beats

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Dow Jones Industrial Average (DJIA)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK -3.79% fell 0.9% in premarket trading Thursday, after the drug maker reported second-quarter adjusted profit that matched expectations, while sales rose above forecasts even as Keytruda sales came up short. Net income fell to $1.55 billion, or 61 cents a share, from $3.00 billion, or $1.18 a share, in the year-ago period. Excluding nonrecurring items, such as a $1.7 billion charge for the acquisition of Pandion Therapeutics, adjusted earnings per share rose to $1.31 from $1.02 to match the FactSet consensus of $1.31. Sales grew 19% to $11.40 billion, above the FactSet consensus of $11.08 billion. Pharmaceutical sales rose 22% to $9.98 billion, while sales of its key cancer treatment Keytruda increased 23% to $4.18 billion but missed expectations of $4.35 billion. For 2021, the company expects adjusted EPS of $5.47 to $5.57, surrounding the FactSet consensus of $5.52, and expects revenue of $46.4 billion to $47.4 billion, above expectations of $46.2 billion. Merck's stock has edged up 0.4% year to date through Wednesday, while the Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA -2.53% has gained 14.1%.

$ 79.16
-3.12 -3.79%
Volume: 18.02M
Nov. 26, 2021 1:10p
P/E Ratio
Dividend Yield
Market Cap
$207.83 billion
Rev. per Employee
US : Dow Jones Global
-905.04 -2.53%
Volume: 325.39M
Nov. 26, 2021 2:12p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.